Stifel initiated coverage on Celldex Therapeutics with a new price target

HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection of mast ce

- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. The data demonstrate that CDX-622 neutralizes both SCF and TSLP, reducing tissue mast cells and inhibiting Type 2 inflammatory responses, supporting its potential to improve clinical activity over s

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -- 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 - HAMPTON, N.J., March 01, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive data on measurements of disease control and quality of life from the Company's Phase 2 barzolvolimab studies in patients with chronic urticaria. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high spe

Morgan Stanley initiated coverage of Celldex Therapeutics with a rating of Overweight and set a new price target of $46.00

UBS initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $44.00

Citigroup initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $70.00

4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

10-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

SCHEDULE 13G - Celldex Therapeutics, Inc. (0000744218) (Subject)

HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin

NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le

First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz

- 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks -- Enrollment to Global Phase 3 CSU trials underway -- Company to host webcast today at 12:00 pm ET/6:00 pm CEST - HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous

- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company's Phase 2 clinical trial of barzolvolim

SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)